101 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
Rank Status Study
21 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
22 Suspended Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Leflunomide
23 Completed NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Condition: Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping
24 Completed Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Conditions: Kidney Cancer;   Melanoma (Skin);   Metastatic Cancer;   Ovarian Cancer;   Sarcoma
Intervention: Radiation: stereotactic radiosurgery
25 Completed SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
26 Unknown  Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Conditions: Malignant Melanoma;   Pancreatic Cancer;   Colon Cancer;   Cervical Cancer
Intervention: Biological: Survivin peptide vaccine
27 Recruiting Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Condition: Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Intervention: Drug: ADI-PEG 20
28 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
29 Completed SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Intervention: Procedure: Surgery
30 Completed A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Conditions: Non-hematologic Malignancies;   Metastatic Melanoma;   Breast Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Hepatocellular Carcinoma
Interventions: Drug: ABT-888;   Drug: Temozolomide
31 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
32 Active, not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
33 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
34 Terminated Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer
Intervention: Biological: ipilimumab
35 Completed
Has Results
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: tipifarnib;   Drug: temsirolimus
36 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: polarized dendritic cells;   Biological: non-polarized dendritic cells
37 Completed Everolimus in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: everolimus
38 Suspended High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa;   Other: clinical observation
39 Recruiting Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel
40 Completed Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Genetic: protein expression analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years